KHK2455

About Kyowa Hakko Kirin

Kyowa Kirin is a publicly traded, global specialty pharma leader with deep roots in Japanese innovation, strategically focused on high-need therapeutic areas including bone & mineral disorders, hematologic malignancies, and rare diseases. Its success is built on proprietary technology platforms like POTELLIGENT® for enhanced antibody therapeutics and the Orchard Therapeutics acquisition for hematopoietic stem cell gene therapy. The company's strategy combines internal R&D excellence with strategic business development to build a sustainable pipeline of transformative medicines, aiming to deliver its 'Vision 2030' of creating life-changing value for patients worldwide.

Therapeutic Areas